skip to Main Content

Texas A&M Innovation recently struck a deal with Sorrento Therapeutics, Inc., a California biopharmaceutical company, for an option to license technologies focused on development of a new COVID-19 therapy developed in the lab of Dr. Wenshe Liu at Texas A&M’s College of Science. Access the full Texas A&M Today story and Sorrento Therapeutics press release through the links below.

Back To Top